Last Updated: June 23, 2026

DOXORUBICIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Doxorubicin patents expire, and when can generic versions of Doxorubicin launch?

Doxorubicin is a drug marketed by Qilu Pharm Hainan, Actavis Inc, Almaject, Amneal, Fresenius Kabi Usa, Gland, Hikma, Hisun Pharm Hangzhou, Hlthcare, Mylan Labs Ltd, Pfizer, Pharmachemie Bv, Pharmobedient, Sagent Pharms, Sun Pharm Inds, Teva Pharms Usa, Alembic, Ayana Pharma Ltd, Baxter Hlthcare Corp, Dr Reddys, Lupin, Sun Pharm, and Zydus Lifesciences. and is included in twenty-seven NDAs.

The generic ingredient in DOXORUBICIN is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for DOXORUBICIN?
  • What are the global sales for DOXORUBICIN?
  • What is Average Wholesale Price for DOXORUBICIN?
Summary for DOXORUBICIN
US Patents:0
Applicants:23
NDAs:27
Drug Prices: Drug price information for DOXORUBICIN
DailyMed Link:DOXORUBICIN at DailyMed
Drug patent expirations by year for DOXORUBICIN
Drug Prices for DOXORUBICIN

See drug prices for DOXORUBICIN

US Patents and Regulatory Information for DOXORUBICIN

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare Corp DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 212219-002 Oct 19, 2022 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sagent Pharms DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 091495-001 Mar 18, 2013 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Lifesciences DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 212299-002 Sep 10, 2020 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lupin DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 215178-002 Jul 16, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pharmachemie Bv DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 063097-002 May 21, 1990 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sun Pharm Inds DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 091418-001 Feb 15, 2012 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pharmachemie Bv DOXORUBICIN HYDROCHLORIDE doxorubicin hydrochloride INJECTABLE;INJECTION 063097-003 May 21, 1990 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for DOXORUBICIN
Sagent pharmaceuticals doxorubicin hydrochloride?
Liposomal doxorubicin price?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links